Bassily-Marcus, AdelBenjamin, ErnestManasia, AnthonyOropello, JohnMurgolo, VictorLeibowitz, AndrewKohli-Seth, Roopa2025-11-192008-12Experimental and Clinical Transplantation, Cilt 6, Sayı 1, 2008, ss. 80-831304-0855https://hdl.handle.net/11727/13922Daclizumab is a commonly used immuno­sup­pressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of brady­cardia following its administration in orthotopic liver transplant.en-USBradyarrhythmiasZenapaxDrug-inducedFamotidineTransplantationArticle612146-8427